MedPlus Health Services Limited disclosed that its subsidiary, Optival Health Solutions Private Limited, received a drug license suspension order from regulatory authorities.
The suspension was ordered by the Assistant Director, Drugs Control Administration, Hyderabad, Telangana, affecting one retail store located at Vijaynagar Colony, Telangana. The order was received on June 19, 2026.
The suspension period is for three days, imposed under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 for alleged violations or contraventions.
The company quantified the financial impact, estimating a potential revenue loss of ₹0.78 lakhs (₹78,000) during the three-day suspension period.
This disclosure was made pursuant to SEBI Listing Regulations and specifically references SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026.
The document was signed by Gangadi Madhukar Reddy, Managing Director and Chief Executive Officer (DIN: 00098097), and will be available on the company's website (www.medplusindia.com) as well as on the BSE and NSE websites.